Tag Archives: Tusamitamab Ravtansine

Sanofi Ceases Development of Tusamitamab Ravtansine for NSCLC after Trial Misses Primary Endpoint

(IN BRIEF) Sanofi has announced the discontinuation of the global clinical development program for tusamitamab ravtansine, following an interim analysis of the Phase 3 CARMEN-LC03 trial. The trial assessed tusamitamab ravtansine as a monotherapy in previously treated metastatic non-squamous non-small … Read the full press release